

## INSTITUTIONAL BIOSAFETY COMMITTEE (IBC)

---

### Meeting Ad hoc Minutes

Date: Wednesday, December 10, 2025

Time: 1:33 PM – 2:00 PM

Location: Zoom - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Members Present:

1. Sydney Gary, Research Operations (*IBC Chairperson*)
2. Janeen Braynen, Computational (*Plant Scientific Advisor*)
3. John Pisciotta, Environmental Health & Safety (*Biological Officer*)
4. Julie Cheong, Assistant Laboratory Building Manager
5. Kenneth Addison, Clinical and Translational Collaborations
6. Lisa Bianco, Laboratory Animal Resources (LAR) (*Technical Operations*)
7. Scott Lyons, Animal Imaging (*Scientific Technical Advisor*)
8. Brian Kelleher (*Community Member, non-CSHL Affiliated*)

Members Not Present:

1. David Jackson, Plant Biology (*Plant Scientific Advisor*)
2. Denise Roberts, Core Operations
3. Rachel Rubino, Laboratory Animal Resources (LAR) (*Attending Veterinarian*)
4. Kristen Panella (*Community Member, non-CSHL Affiliated*)

Non-Voting Attendees Present:

1. Joanie O'Connor, Administrative & Regulatory Coordinator
2. Angelina Regua, Research Compliance Officer (IRB)
3. Julie Sutherland, Conflict of Interest and Compliance Coordinator
4. Xiomara Medina, IACUC Administrator/Manager

### Commonly Used Abbreviations

AAV: Adeno-associated viral vector

BSL: Biosafety level

BSO: Biosafety Officer

CRISPR: Clustered regularly interspaced short palindromic repeats

DMR: Designated Member Review

DURC: Dual Use Research of Concern

FCR: Full Committee Review

IACUC: Institutional Animal Care and Use Committee

IBC: Institutional Biosafety Committee

IRB: Institutional Review Board

NIH: National Institutes of Health

PI: Principal Investigator

PPE: Personal protective equipment

r/s NAM: Recombinant or synthetic nucleic acid molecules

RG: Risk Group

SOP: Standard Operating Procedures

Source material: blood, tissue, cell lines

**1 CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chairperson called the meeting to order at 1:33 PM. A quorum was present.

**2 APPROVAL OF MINUTES:**  
No previous minutes to approve.

**3 INDIVIDUAL PROJECT REVIEWS (FCR):**

3.1 Tobias Janowitz, amendment, IBC-2024-7, *Immunological, dietary, endocrinological, physiological and pharmacological regulation of anti-cancer immunity*

- NIH Guidelines Section III-D
- The Janowitz lab investigates the connections between metabolism, endocrinology, and immunology to discover how the body's response to a tumor can be used to improve treatment for patients with cancer.
- This project has an approved IACUC protocol number 2023-1329.
- A proper risk assessment has been performed, and the following applicable agents, their characteristics and sources, hosts, modifications, recommended biosafety containment levels, and other pertinent details have been reviewed for the potential risks associated with the protocol to ensure a safe and responsible research environment.
- PPE will be worn as dictated by the biosafety level of the research.
- The Committee unanimously approved the amendment with an 8-0-0 vote (for, against, abstained), pending the completion of the items listed below.
  - Confirm whether the AAV will be packaged or propagated in-house and provide the name of the commercial source.
  - Confirm the injection volume for the gastrocnemius muscle injections in mice and whether the volume based on the AAV titer is supplied by the commercial source.

BSL-2 Use of replication defective AAV in mouse (Apelin overexpression).

- Training: All personnel have completed the required biological training in accordance with institutional and NIH guidelines.
- All pending items were addressed post-meeting.
- The protocol was approved effective December 10, 2025. The approval letter was generated on December 15, 2025, after the required information had been provided.

3.2 Bo Li, amendment, IBC-2022-4, *Brain and Body and Behavior*

- NIH Guidelines Section III-D
- The Li lab investigates the neural circuits underlying cognitive function and dysfunction as they relate to anxiety, depression, schizophrenia, and autism.
- This project has an approved IACUC protocol number 2021-1185.
- A proper risk assessment has been performed, and the following applicable agents, their characteristics and sources, hosts, modifications, recommended biosafety containment levels, and other pertinent details have been reviewed for the potential risks associated with the protocol to ensure a safe and responsible research environment.
- PPE will be worn as dictated by the biosafety level of the research.
- The Committee unanimously approved the amendment with an 8-0-0 vote (for, against, abstained), pending the completion of the item listed below:
  - Confirm the tropism of the Pseudorabies Virus (PRV) strain.
  - Provide a brief description of the term "attenuated," as it may have a specific meaning in the context of viruses.

BSL-2 Use of pseudorabies virus in animal models.

- Training: All personnel have completed the required biological training in accordance with institutional and NIH guidelines.
- All pending items were addressed post-meeting.
- The protocol was approved effective December 10, 2025. The approval letter was generated on December 11, 2025, after the required information had been provided.

### 3.3 Hannah Meyer, amendment, IBC-2024-1, *T Cell Tolerance Induction and Thymic Physiology*

- NIH Guidelines Section III-D
- The Meyer lab applies a systems immunology approach to investigating the mechanisms underlying thymic selection.
- This project has an approved IACUC protocol number 2025-1459.
- A proper risk assessment has been performed, and the following applicable agents, their characteristics and sources, hosts, modifications, recommended biosafety containment levels, and other pertinent details have been reviewed for the potential risks associated with the protocol to ensure a safe and responsible research environment.
- PPE will be worn as dictated by the biosafety level of the research.
- The Committee unanimously approved the amendment with an 8-0-0 vote (for, against, abstained), pending the completion of the item listed below:
  - Specify the pseudorabies virus strain(s) to be used in mice.
- BSL-2 Use of pseudorabies virus in mice using ultrasound-guided intrathymic injections.
- Training: All personnel have completed the required biological training in accordance with institutional and NIH guidelines.
- All pending items were addressed post-meeting.
- The protocol was approved effective December 10, 2025. The approval letter was generated on December 11, 2025, after the required information had been provided.

## 4 DESIGNATED MEMBER REVIEW (DMR):

### 4.1 Paolo Ciffani, annual review, IBC-2024-19, *Development of MS approaches for advanced proteomic analyses*

- NIH Guidelines Section III-D
- The Cifani lab develops innovative approaches to study protein regulation using high-resolution mass spectrometry and liquid chromatography.
- A proper risk assessment has been performed, and the following applicable agents, their characteristics and sources, hosts, modifications, recommended biosafety containment levels, and other pertinent details have been reviewed for the potential risks associated with the protocol to ensure a safe and responsible research environment.
- PPE will be worn as dictated by the biosafety level of the research.
- In the annual review, which resulted in no protocol changes, the Committee unanimously approved the IBC submission and use of agents as described, with a vote of 8-0-0 (for, against, abstained).
- BSL-1 Proteome extraction from immortalized cells growing in vitro.
- Training: All personnel have completed the required biological training in accordance with institutional and NIH guidelines.
- The protocol was approved, effective December 10, 2025.

#### 4.2 Bo Li, annual review, IBC-2022-4, *Brain and Body and Behavior*

- NIH Guidelines Section III-D
- The Li lab investigates the neural circuits underlying cognitive function and dysfunction as they relate to anxiety, depression, schizophrenia, and autism.
- A proper risk assessment has been performed, and the following applicable agents, their characteristics and sources, hosts, modifications, recommended biosafety containment levels, and other pertinent details have been reviewed for the potential risks associated with the protocol to ensure a safe and responsible research environment.
- PPE will be worn as dictated by the biosafety level of the research.
- In the annual review, which resulted in no protocol changes, the Committee unanimously approved the IBC submission and use of agents as described, with a vote of 8-0-0 (for, against, abstained).

BSL-1 Standard subcloning and bacterial expression work.

BSL-1 Use of ecotropic, replication defective adeno-associated virus to infect animal models.

BSL-2 Use of ecotropic, replication defective canine adenovirus expressing Cre in animal models.

BSL-2 Use of ecotropic, replication defective herpes simplex virus expressing fluorescent protein in animal models.

BSL-2 Use of ecotropic, replication defective Sindbis virus expressing Barcoded RNA in animal models at BSL-2.

BSL-2 Use of *Heligmosomoides polygyrus* to infect animal models.

BSL-2+ Use of ecotropic, replication defective rabies virus (the pSAD  $\delta$ G (EnvA) form).

BSL-2+ Use of amphotropic, replication defective lentivirus to express CRISPR-cas9 and sgRNA targeting IL-6Ra promoter in animal models.

BSL-2+ Use of amphotropic, replication defective yellow fever virus (YFV-17D).

BSL-2+ Use of amphotropic, yellow fever virus mutant, YFV-mVenus, derived from YFV-17D, which are replication- or packaging-deficient to express a fluorescent protein or Cre.

- Training: All personnel have completed the required biological training in accordance with institutional and NIH guidelines.
- The protocol was approved effective December 10, 2025.

## 5 CONTINUING EDUCATION

5.1 Recap of the Safe-tober Escape Room: Biosafety Awareness Day that took place on October 28, 2025.

- Dr. Gary indicated that the event was a tremendous success and thanked everyone who worked on it. It was both educational and fun; the feedback was positive, and there was a suggestion to make it longer. There has been discussion about next year's theme.

## 6 PUBLIC COMMENTS

6.1 For security reasons, Cold Spring Harbor Laboratory has an institutional policy that information regarding IBC meeting times and locations is not publicly available. Any member of the public requesting IBC information is kindly requested to contact the CSHL Office of Research Compliance at [ResearchCompliance@cshl.edu](mailto:ResearchCompliance@cshl.edu).

## 7 MEETING ADJOURNED AT APPROXIMATELY 2:00 PM.